Organon (OGN) Change in Account Payables (2020 - 2026)
Organon (OGN) recorded quarterly Change in Account Payables of $32.0 million in Q1 2026, up 126.67% quarter-over-quarter from -$120.0 million in Q4 2025, and up 121.48% on a YoY basis from $14.4 million in Q1 2025.
Organon (OGN) Change in Account Payables (2020 - 2026) Analysis & Trends
Organon's Change in Account Payables history runs 7 years deep, the most recent figure standing at $32.0 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 121.48% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at -$36.0 million (down 183.72% YoY), while the FY2025 annual figure was -$217.0 million, down 38.22% from the prior year.
- Change in Account Payables was $32.0 million for Q1 2026 at Organon, up from -$120.0 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $293.0 million in Q2 2024 to a low of -$349.0 million in Q1 2024.
- Historically, Change in Account Payables has averaged -$24.5 million across 5 years, with a median of $12.0 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables plunged 7550.0% in 2022, then soared 168.6% in 2023.
- A 5-year view of Change in Account Payables shows it stood at $86.0 million in 2022, then soared by 168.6% to $231.0 million in 2023, then slumped by 74.89% to $58.0 million in 2024, then plunged by 306.9% to -$120.0 million in 2025, then soared by 126.67% to $32.0 million in 2026.
- The last three Change in Account Payables figures came in at $32.0 million (Q1 2026), -$120.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | - |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | - |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | - |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 409.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 32.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.00 Mn |
| Mar 31, 2026 | 32.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Mar 31, 2024 | -349.00 Mn |
| Mar 31, 2024 | -349.00 Mn |
| Dec 31, 2023 | 231.00 Mn |
| Dec 31, 2023 | 231.00 Mn |